| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA803: Risankizumab for treating active psoriatic arthritis after inadequate response to DMARDs |
|
Medicine details |
|
| Medicine name | risankizumab (Skyrizi®) |
| Formulation | 75 mg, 150 mg solution for injection in pre-filled syringe, 150 mg solution for injection in pre-filled pen |
| Reference number | 3415 |
| Indication | Alone or in combination with methotrexate (MTX), indicated for the treatment of active psoriatic arthritis in adults who have had an inadequate response or who have been intolerant to one or more disease-modifying antirheumatic drugs (DMARDs) |
| Company | AbbVie Ltd |
| BNF chapter | Skin |
| Submission type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 09/12/2021 |
| NICE guidance | TA803: Risankizumab for treating active psoriatic arthritis after inadequate response to DMARDs |
| Commercial arrangement | PAS |